ArticlePloS one2014
ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cells.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Functional significance of miR-218 in lung cancer.Journal of cancer metastasis and treatment · 2026Article
- Potential Influence ofInternational journal of molecular sciences · 2025Article
- MiR-22-3p suppresses NSCLC cell migration and EMT via targeting RAC1 expression.Functional & integrative genomics · 2023Article
- Inhibition of CDCP1 by 8-isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment.Molecular oncology · 2023Article
- Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.Biomolecules · 2022Article
- The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant Ovarian Cancer Cell Lines.International journal of molecular sciences · 2022Article
- Identification of theranostic factors for patients developing metastasis after surgery for early-stage lung adenocarcinoma.Theranostics · 2021Article
- The emerging role of the MiR-1272-ADAM9-CDCP1 signaling pathway in the progression of glioma.Aging · 2020Article
- Primary tumor and metastasis-sectioning the different steps of the metastatic cascade.Translational lung cancer research · 2020Review
- miR-218 Inhibits Mitochondrial Clearance by Targeting PRKN E3 Ubiquitin Ligase.International journal of molecular sciences · 2020Article
- Resveratrol-mediated ADAM9 degradation decreases cancer progression and provides synergistic effects in combination with chemotherapy.American journal of cancer research · 2020Article
- Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis.Scientific reports · 2019Article
- MicroRNA-425 promotes the development of lung adenocarcinoma via targeting A disintegrin and metalloproteinases 9 (ADAM9).OncoTargets and therapy · 2018Article
- Crosstalk in competing endogenous RNA network reveals the complex molecular mechanism underlying lung cancer.Oncotarget · 2017Article
- Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.Oncotarget · 2017Article
- MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer.Oncotarget · 2017Article
- Identification of microRNAs as potential biomarkers for lung adenocarcinoma using integrating genomics analysis.Oncotarget · 2017Article
- [MiR-218 Inhibits Migration and Invasion of Lung Cancer Cell by Regulating Robo1 Expression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Article
- ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.Oncotarget · 2017Article
- Alternative new mesenchymal stem cell source exerts tumor tropism through ALCAM and N-cadherin via regulation of microRNA-192 and -218.Molecular and cellular biochemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer death worldwide, and brain metastasis is a major cause of morbidity and mortality in lung cancer. CDH2 (N-cadherin, a mesenchymal marker of the epithelial-mesenchymal transition) and ADAM9 (a type I transmembrane protein) are related to lung cancer brain metastasis; however, it is unclear how they interact to mediate this metastasis. Because microRNAs regulate many biological functions and disease processes (e.g., cancer) by down-regulating their target genes, microRNA microarrays were used to identify ADAM9-regulated miRNAs that target CDH2 in aggressive lung cancer cells. Luciferase assays and western blot analysis showed that CDH2 is a target gene of miR-218. MiR-218 was generated from pri-mir-218-1, which is located in SLIT2, in non-invasive lung adenocarcinoma cells, whereas its expression was inhibited in aggressive lung adenocarcinoma. The down-regulation of ADAM9 up-regulated SLIT2 and miR-218, thus down-regulating CDH2 expression. This study revealed that ADAM9 activates CDH2 through the release of miR-218 inhibition on CDH2 in lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.